Trials / Completed
CompletedNCT02534350
Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection
A Phase 2b, Randomized, Controlled Trial Evaluating GS-5806 in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the effect of presatovir on nasal respiratory syncytial virus (RSV) viral load in RSV-positive lung transplant (LT) recipients with acute respiratory symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Presatovir | Tablets administered orally or via nasogastric (NG) tube once daily |
| DRUG | Placebo | Tablets administered orally or via NG tube once daily |
Timeline
- Start date
- 2015-12-31
- Primary completion
- 2017-02-20
- Completion
- 2017-09-27
- First posted
- 2015-08-27
- Last updated
- 2018-11-28
- Results posted
- 2018-11-28
Locations
28 sites across 8 countries: United States, Australia, Belgium, Canada, France, Germany, Netherlands, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02534350. Inclusion in this directory is not an endorsement.